Loading clinical trials...
Loading clinical trials...
Controlled-Release Misoprostol Vaginal Insert in Parous Women for Labor Induction: Randomized Trial
The primary objective of the study was assessment of the efficacy of four dose reservoirs (25 mcg, 50 mcg, 100 mcg, 200 mcg) of intravaginal controlled release misoprostol administered for up to 24 hours. Efficacy was measured in terms of time from insert placement to vaginal delivery.
Approximately 20% of pregnant women require medical intervention to induce labour for reasons including post-date pregnancy, pre-eclampsia, maternal diabetes, premature rupture of the membranes and intra-uterine fetal growth retardation. There are two fundamental changes that characterise pre-labour preparation for delivery: sensitisation of the myometrium to produce contractions, and ripening (softening and dilation) of the cervix. Prostaglandins (PG) are fundamental to both of these changes, and several forms have been used to successfully induce labour. Dinoprostone (PGE2) is an example of a cervical ripening agent that is available in gel and tablet form and has a proven record of successful cervical ripening in this population. Dinoprostone is also available in a controlled release vaginal delivery system, which is manufactured by Controlled Therapeutics (Scotland) a subsidiary of Cytokine PharmaSciences, Inc., King of Prussia, PA, USA. Another synthetic prostaglandin that has been shown to be an effective cervical ripener and labour inducer is misoprostol. Oral tablets are broken into fragments and used intravaginally to ripen the cervix and induce labour Due to the disadvantages of existing cervical ripeners (delivery of bolus doses, freezer or refrigerated storage, lack of efficacy in labour induction), and due to safety concerns with the off-label use of oral misoprostol tablet fragments, Controlled Therapeutics has developed a controlled release vaginal delivery system similar to its marketed dinoprostone product but containing misoprostol. This study examines four dose strengths of the misoprostol vaginal insert in women who need to have their labours induced.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Birmingham Women's Hospital
Birmingham, United Kingdom
Princess Royal Maternity Hospital
Glasgow, United Kingdom
King George Hospital
Ilford, United Kingdom
Liverpool Women's Hospital
Liverpool, United Kingdom
Northampton General Hospital
Northampton, United Kingdom
The Queen's Mother's Hospital
Yorkhill, Glasgow, United Kingdom
Start Date
June 1, 2003
Primary Completion Date
February 1, 2004
Completion Date
March 1, 2004
Last Updated
June 18, 2012
124
ACTUAL participants
Misoprostol vaginal insert 25 mcg
DRUG
Misoprostol vaginal insert 50 mcg
DRUG
Misoprostol vaginal insert 100 mcg
DRUG
Misoprostol vaginal insert 200 mcg
DRUG
Lead Sponsor
Ferring Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06809985